The potential economic value of a Staphylococcus aureus vaccine for neonates

Area of Science:

• Infectious Diseases
• Vaccinology
• Health Economics

Background:

• * Staphylococcus aureus (S. aureus) infections, including methicillin-resistant S. aureus (MRSA), cause significant morbidity and mortality.
• * There is a critical need for effective interventions, such as vaccines, to combat S. aureus.
• * Neonatal populations are particularly vulnerable to S. aureus infections.

Purpose of the Study:

• * To evaluate the potential economic impact of a S. aureus vaccine specifically for neonates.
• * To determine the cost-effectiveness of a S. aureus vaccine across various scenarios.
• * To inform vaccine development priorities for S. aureus.

Main Methods:

• * Development of a decision analytic computer simulation model.
• * Simulation of economic outcomes associated with a neonatal S. aureus vaccine.
• * Analysis of cost-effectiveness under varying vaccine efficacy and attack rates.

Main Results:

• * A S. aureus vaccine for neonates is strongly cost-effective across a broad range of parameters.
• * The vaccine is dominant in many scenarios, indicating superior health outcomes and lower costs.
• * Cost-effectiveness is maintained even with vaccine efficacies as low as 10% and S. aureus attack rates of 1%.

Conclusions:

• * A neonatal S. aureus vaccine represents a highly valuable public health intervention.
• * The economic benefits support prioritizing S. aureus vaccine development.
• * The model demonstrates favorable cost-effectiveness for a S. aureus vaccine in the neonatal population.